Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | AHR | P35869 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4524559 | 0.84 | L3MBTL1 (0.57) | HPGDLMNAL3MBTL1HTTSMN1; SMN2 | |
| SCHEMBL561284 | 0.83 | HTT (0.64) | GAAHPGDLMNAAHRHTT | |
| SCHEMBL13139930 | 0.82 | L3MBTL1 (0.58) | HPGDL3MBTL1SMN1; SMN2POLBMEN1 | |
| SCHEMBL8762477 | 0.82 | HTT (0.59) | GAAHPGDLMNAAHRHTT | |
| SCHEMBL3071849 | 0.81 | L3MBTL1 (0.63) | HPGDLMNAL3MBTL1SMN1; SMN2MEN1 | |
| SCHEMBL2367399 | 0.81 | HTT (0.63) | GAAHPGDLMNAAHRHTT | |
| SCHEMBL8291434 | 0.80 | GAA (0.60) | GAAHPGDLMNAAHRHTT | |
| Methyl 3,5-Dinitrobenzoate SCHEMBL418416 | 0.80 | SMN1; SMN2 (0.60) | GAAHTTSMN1; SMN2POLBMEN1 | |
| SCHEMBL3080624 | 0.80 | L3MBTL1 (0.62) | HPGDL3MBTL1SMN1; SMN2POLBMEN1 | |
| SCHEMBL12443197 | 0.80 | L3MBTL1 (0.62) | HPGDL3MBTL1SMN1; SMN2POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | PLE PATRICK | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | AQP3, AQP1, F12 | GAA 3392/4885HPGD 684/4885LMNA 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.